An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Key Points
Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2, 2026.
This transaction consisted entirely of directly held shares.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating a pre-scheduled liquidity event.
- 10 stocks we like better than Adaptive Biotechnologies ›
Harlan S. Robins, the chief scientific officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), sold 386,240 shares of common stock at $22.01 per share on July 2, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $8.5 million |
| Shares sold (directly held) | 386,240 |
| Post-transaction shares (directly held) | 1,019,658 |
| Post-transaction value | $21.61 million |
Key questions
- What was the mechanism for this transaction?
The sale was conducted under a Rule 10b5-1 trading plan established on March 13, 2026, which allows corporate insiders to set a predetermined schedule for selling shares to avoid potential conflicts regarding material non-public information. - How does the transaction price compare to the current market level?
Robins sold shares at a weighted average price of $22.01, while the stock was priced at $21.50 as of the July 6, 2026, market close. - What is the status of the insider's remaining equity position?
After disposing of the roughly 386,000 shares, Robins continues to hold 1,019,658 shares directly, representing a post-transaction market value of $21.61 million. - What has been the stock's recent performance trajectory?
As of the transaction date on July 2, 2026, Adaptive Biotechnologies Corporation had generated a one-year total return of 85%.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-07-06) | $21.50 |
| Market Capitalization | $3.3 billion |
| Revenue (TTM) | $295.4 million |
| Net Income (TTM) | -$49.7 million |
Company Snapshot
- Adaptive Biotechnologies develops and commercializes an immune medicine platform anchored by its immunoSEQ immunosequencing technology, which enables precise diagnosis and treatment of a broad spectrum of diseases through immune profiling and T-cell receptor analysis.
- The company generates revenue through licensing its proprietary immunosequencing platform to diagnostic and therapeutic partners, conducting research collaborations, and offering clinical and research services that leverage its advanced immune profiling capabilities.
- Adaptive Biotechnologies serves pharmaceutical companies, academic research institutions, clinical laboratories, and healthcare systems seeking to develop personalized immunotherapies and advance precision medicine approaches in oncology and immunological disorders.
Adaptive Biotechnologies is a commercial-stage biotechnology company investing heavily in research and development, as evidenced by its TTM net loss of $49.7 million. The company's competitive advantage lies in its proprietary immunosequencing platform, which provides unparalleled insights into immune system composition and function, positioning it as a critical infrastructure provider for the emerging field of immune medicine and personalized therapeutics.
What this transaction means for investors
Robins, the brother of CEO Chad Robins, let go of more than 386,000 shares under a plan he set in March, and while that's a solid chunk, he still holds more than a million shares worth around $21.6 million. Of course, a founding family's selling is worth tracking as a pattern, but a preset sale that leaves this much on the table reads more as diversification.
Meanwhile, Adaptive’s business is finally turning the corner. Adaptive has pivoted hard toward its MRD diagnostics engine, where its clonoSEQ cancer test helpd drive first-quarter revenue up 35% to $70.9 million and volume up 41%. The net loss narrowed to $20 million, and management raised full-year MRD guidance to $260 million to $270 million. Management credited stronger-than-expected clinical volume for the bump. Ultimately, this seems like a real growth story with a widening path to profitability. Unless family selling really accelerates, it doesn’t seem like this type of transaction should warrant too much attention.
Should you buy stock in Adaptive Biotechnologies right now?
Before you buy stock in Adaptive Biotechnologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Adaptive Biotechnologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $395,679!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,805!*
Now, it’s worth noting Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of July 12, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
